Inhibition of UDP-Glucuronosyltransferase (UGT) Isoforms by Arctiin and Arctigenin

详细信息    查看全文

• 作者：Hui Zhang ; Zhenying Zhao ; Tao Wang ; Yijia Wang ; Xiao Cui ; Huijuan Zhang and Zhong-Ze Fang
• 刊名：Phytotherapy Research
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：30
• 期：7
• 页码：1189-1196
• 全文大小：406K
• ISSN：1099-1573

文摘

Arctiin is the major pharmacological ingredient of Fructus Arctii, and arctigenin is the metabolite of arctiin formed via the catalysis of human intestinal bacteria. The present study aims to investigate the inhibition profile of arctiin and arctigenin on important phase II drug-metabolizing enzymes UDP-glucuronosyltransferases (UGTs), indicating the possible herb–drug interaction. In vitro screening experiment showed that 100 μM of arctiin and arctigenin inhibited the activity of UGT1A3, 1A9, 2B7, and 2B15. Homology modeling-based in silico docking of arctiin and arctigenin into the activity cavity of UGT2B15 showed that hydrogen bonds and hydrophobic interactions contributed to the strong binding free energy of arctiin (−8.14 kcal/mol) and arctigenin (−8.43 kcal/mol) with UGT2B15. Inhibition kinetics study showed that arctiin and arctigenin exerted competitive and noncompetitive inhibition toward UGT2B15, respectively. The inhibition kinetic parameters (K_i) were calculated to be 16.0 and 76.7 μM for the inhibition of UGT2B15 by arctiin and arctigenin, respectively. Based on the plasma concentration of arctiin and arctigenin after administration of 100 mg/kg of arctiin, the [I]/K_i values were calculated to be 0.3 and 0.007 for arctiin and arctigenin, respectively. Based on the inhibition evaluation standard ([I]/K_i < 0.1, low possibility; 0.1 < [I]/K_i < 1, medium possibility; [I]/K_i > 1, high possibility), arctiin might induce drug–drug interaction with medium possibility. Based on these results, clinical monitoring the utilization of Fructus Arctii is very important and necessary. Copyright